<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Thermo Fisher &#8211; Healthcare Asia Daily News &#8211; Asia&#039;s Leading News and Information Source on Healthcare and Medical Industry, Medical Technology, Healthcare Business and R&amp;D, Healthcare Events. Online since 2010</title>
	<atom:link href="https://www.healthcareasia.org/tag/thermo-fisher/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.healthcareasia.org</link>
	<description>Connecting people to news &#38; information on Asian healthcare</description>
	<lastBuildDate>Fri, 28 Jun 2024 09:03:56 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.healthcareasia.org/wp-content/uploads/2026/06/cropped-HCA_favicon-32x32.png</url>
	<title>Thermo Fisher &#8211; Healthcare Asia Daily News &#8211; Asia&#039;s Leading News and Information Source on Healthcare and Medical Industry, Medical Technology, Healthcare Business and R&amp;D, Healthcare Events. Online since 2010</title>
	<link>https://www.healthcareasia.org</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Thermo Fisher, NUH, and Mirxes Enhance Genomic Testing for Early Cancer Detection in Singapore</title>
		<link>https://www.healthcareasia.org/2024/thermo-fisher-nuh-and-mirxes-enhance-genomic-testing-for-early-cancer-detection-in-singapore/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Fri, 28 Jun 2024 09:03:56 +0000</pubDate>
				<category><![CDATA[Technology & Devices]]></category>
		<category><![CDATA[Early Cancer Detection]]></category>
		<category><![CDATA[featured]]></category>
		<category><![CDATA[Mirxes]]></category>
		<category><![CDATA[NUH]]></category>
		<category><![CDATA[Thermo Fisher]]></category>
		<guid isPermaLink="false">https://www.healthcareasia.org/?p=39855</guid>

					<description><![CDATA[Thermo Fisher Scientific, National University Hospital (NUH), and RNA technology company Mirxes have signed a Memorandum of Understanding (MOU) to increase access to affordable, advanced genomic testing for cancer in Singapore. This partnership aims to develop and clinically validate next-generation [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" class="alignleft  wp-image-39856" src="https://www.healthcareasia.org/wp-content/uploads/2024/06/Thermo-Fisher.jpg" alt="Thermo Fisher, NUH, and Mirxes Enhance Genomic Testing for Early Cancer Detection in Singapore" width="233" height="140" />Thermo Fisher Scientific, National University Hospital (NUH), and RNA technology company Mirxes have signed a Memorandum of Understanding (MOU) to increase access to affordable, advanced genomic testing for cancer in Singapore. This partnership aims to develop and clinically validate next-generation sequencing (NGS) solutions tailored for the Southeast Asian population, addressing the limited access to rapid NGS testing in the region.</p>
<p>The collaboration leverages NUH’s clinical expertise and the biotechnology advancements of Thermo Fisher and Mirxes. Associate Professor Tan Soo Yong of NUH highlighted the potential of this partnership to refine early detection methods and deliver precise diagnoses and treatments for cancer. Thermo Fisher&#8217;s Sho-Wen Yeo highlighted the ability to provide fast NGS results, aiding in precision medicine for better cancer treatment decisions. Mirxes CEO, Dr Zhou Lihan, noted the company’s commitment to precision medicine and their investment in multi-omic and NGS capabilities for early cancer detection.</p>
<p>Related: B<a href="https://www.healthcareasia.org/2024/breakthrough-discovery-of-key-enzymes-role-in-rna-modification-and-cancer/">reakthrough Discovery of Key Enzyme’s Role in RNA Modification and Cancer</a></p>
<p>Currently, the NUH Diagnostic Molecular Oncology Centre offers NGS testing for four common cancers and plans to expand access throughout Southeast Asia.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>TTSH, Thermo Fisher collaboration advances precision medicine, genetic testing</title>
		<link>https://www.healthcareasia.org/2023/ttsh-thermo-fisher-collaboration-advances-precision-medicine-genetic-testing/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 17 Aug 2023 03:41:45 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[featured]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Thermo Fisher]]></category>
		<category><![CDATA[TTSH]]></category>
		<guid isPermaLink="false">https://www.healthcareasia.org/?p=39068</guid>

					<description><![CDATA[Singapore&#8217;s Tan Tock Seng Hospital (TTSH) is partnering with Thermo Fisher Scientific to enhance clinical research through advanced multiple-gene testing, a field known as pharmacogenomics (PGx). PGx testing focuses on how genes influence responses to medications, aiding clinicians in making [&#8230;]]]></description>
										<content:encoded><![CDATA[<p><img decoding="async" class="alignleft  wp-image-39069" src="https://www.healthcareasia.org/wp-content/uploads/2023/08/medicine.jpg" alt="TTSH, Thermo Fisher collaboration advances precision medicine, genetic testing" width="254" height="176" />Singapore&#8217;s Tan Tock Seng Hospital (TTSH) is partnering with Thermo Fisher Scientific to enhance clinical research through advanced multiple-gene testing, a field known as pharmacogenomics (PGx). PGx testing focuses on how genes influence responses to medications, aiding clinicians in making informed treatment decisions for patients. TTSH, a pioneer in PGx testing, previously offered single-gene and small-panel tests, which led to multiple tests and higher costs. The collaboration with Thermo Fisher allows for simultaneous assessment of multiple genes and the use of polygenic risk scores (PRS) to measure disease risk based on genetics, reducing the need for multiple tests and costs.</p>
<p>The partnership expands TTSH&#8217;s Molecular Diagnostic Laboratory (MDL) capabilities, potentially leading to innovative population health solutions. In 2024, MDL and TTSH will conduct a unique three-year research trial using PRS to predict heart disease in the local population. The precision medicine approach aligns with Singapore&#8217;s Research, Innovation, and Enterprise 2025 vision, aiming for preventative healthcare in line with the Healthier SG reform plan. Dr. Goh Liuh Ling of TTSH emphasizes early intervention and cost savings, while Fadjar Linawati of Thermo Fisher highlights the shift to personalized medicine. Educational programs and training will further raise awareness and develop local talent in navigating transformative healthcare approaches.</p>
<div style="visibility: hidden; position: absolute; margin-top: -100px;"><a href="https://twitter.com/healthcareasia">Health Care Asia</a><br />
<a href="https://www.healthcareasia.org/">Home</a><br />
<img decoding="async" src="https://www.healthcareasia.org/wp-content/uploads/2017/03/HCA-logo.jpg" alt="Health Care Asia" /></div>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
